Cutting Edge Research in Stem Cells and Cancer Immunotherapy to Be Presented at the 2nd Annual Cancer Immunotherapy …

MINNEAPOLIS--(BUSINESS WIRE)--

Ground breaking research on cancer stem cells as targets and normal stem cells in Immunotherapy will be discussed at the 2nd Annual Cancer Immunotherapy Conference in Washington DC on April 4-5, 2013.

As modern oncology, largely directed towards developing therapies that achieve tumor reduction, has been thus far unsuccessful in achieving long term management of cancer, much more needs to be done in identifying and appropriately leveraging targets associated with tumor initiation, relapse or metastasis. Immunotherapy holds the promise of achieving durable control of cancer if matched with appropriate targets borne by cancer cells responsible for relapse and metastasis.

At the 2nd Annual Cancer Immunotherapy Conference, significant findings on hematopoietic stem cells and T cell engineering for cancer immunotherapy, as well as cancer stem cells as a new category of targets for immune intervention in solid and hematological malignancies will be presented by nearly twenty experts in the fields of academia, pharmaceuticals and cancer research.

Speakers and panelists will be addressing and answer the following questions:

Some of the speakers at this years conference include:

This conference brings together leading scientists and C-Level executives from across the globe to present ground breaking research, case studies and new viewpoints. Please visit http://www.cancerimmunotherapyconference.com for the full list of speakers, agenda, and registration information.

See original here:
Cutting Edge Research in Stem Cells and Cancer Immunotherapy to Be Presented at the 2nd Annual Cancer Immunotherapy ...